search results
Image 32 of 71
Less

ET-D5_009.jpg

Add to Lightbox Download

Dr Aurélie Juhem is observing cancer cells incubated with ET-D5 using fluorescence microscopy

Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.
Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.

Copyright
Bruno Vigneron
Image Size
5000x3337 / 11.4MB
Keywords
Contained in galleries
ET-D5
Dr Aurélie Juhem is observing cancer cells incubated with ET-D5 using fluorescence microscopy<br /> <br /> Dr Aurélie JUHEM met Dr Andrei Popov in 2005 to start her PhD training in his research team. They develop an innovative screening strategy to identify new anti-proliferative drugs targeting cell divison from a chemical library provided by the Institut Curie. They identified further new bioactive chemical entities including an ET-D5 structural analogue. Graduated in 2008 from Joseph Fourier University (Grenoble), she continued ET-D5 research program as a postdoctoral researcher with Dr Popov. This work was patented in 2010 and Ecrins therapeutics was founded to develop ET-D5 under preclinical studies.<br /> Since 2010, Dr Aurelie Juhem is the R&D Director of Ecrins Therapeutics.